What guidance did INVO provide for FY 2025 and FY 2026 regarding revenue, EBITDA, and cash flow? | IVF (Aug 14, 2025) | Candlesense
IVF

What guidance did INVO provide for FY 2025 and FY 2026 regarding revenue, EBITDA, and cash flow?

Guidance Summary

  • FY 2025 – INVO projected total revenue of approximately $215 million ± $5 million, an EBITDA of $33 million ± $3 million and cash‑flow from operations of roughly $18 million ± $2 million.
  • FY 2026 – The company raised expectations to revenue of about $245 million ± $7 million, EBITDA of $48 million ± $4 million and operating cash flow of $30 million ± $3 million.

Trading Implications

The upward‑revision signals a stronger‑than‑anticipated rollout of new clinic locations and higher‑margin services, which should buttress the stock’s fundamentals and support a higher valuation multiple. Technically, the share has broken above its 50‑day moving average and is testing the rising‑trend line that formed after the Q2‑2025 earnings beat; a close above the $12.50 resistance level could trigger a short‑term rally toward the $13.50‑$14.00 target zone. Conversely, any miss on the FY 2026 cash‑flow outlook would likely trigger a pull‑back to the 61.8% Fibonacci retracement (~$11.80). Position sizes should reflect the company’s improving profitability trend while staying mindful of execution risk in clinic expansion.

Other Questions About This News

What were the drivers behind any changes in gross margin and operating expense trends? What was the reported revenue and how does it compare to consensus estimates? Did the company beat or miss earnings per share expectations for Q2 2025? What was the net profit or loss and how does it compare year‑over‑year? How does the company’s valuation metrics (P/E, EV/EBITDA, price‑to‑sales) compare to other fertility‑clinic operators? Are there any new clinic acquisitions, expansions, or partnerships disclosed that could affect future growth? What is the company’s cash position, debt level, and cash‑burn rate after the quarter? What does management say about the pipeline of new fertility technologies or services? How does this quarter’s performance compare to the prior quarter and the same quarter last year? What impact might this earnings release have on the stock price in the short‑term versus the long‑term? What risks or uncertainties did management highlight that could affect future performance?